Declining rates of treatment-related mortality in patients with newly diagnosed AML given 'intense' induction regimens: a report from SWOG and MD Anderson.
Open Access
- 13 June 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 28 (2), 289-92
- https://doi.org/10.1038/leu.2013.176
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Combination of Azacitidine and Lenalidomide in Myelodysplastic Syndromes or acute Myeloid Leukemia—a wise Liaison?Leukemia, 2013
- Prediction of Early Death After Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia With Pretreatment Risk Scores: A Novel Paradigm for Treatment AssignmentJournal of Clinical Oncology, 2011
- Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemiaLeukemia, 2010
- Reduced Mortality after Allogeneic Hematopoietic-Cell TransplantationNew England Journal of Medicine, 2010
- Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigmBlood, 2010
- Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid LeukemiaJournal of Clinical Oncology, 2010
- A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatmentCancer, 2007
- Age and acute myeloid leukemiaBlood, 2006
- Caspofungin versus Liposomal Amphotericin B for Empirical Antifungal Therapy in Patients with Persistent Fever and NeutropeniaNew England Journal of Medicine, 2004
- Prevention and therapy of fungal infections in bone marrow transplantationLeukemia, 2003